MHRA (UK) approves Yselty to treat symptoms of uterine fibroids.- ObsEva SA.
ObsEva SA announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization for Yselty (linzagolix), an oral GnRH antagonist, for the management of moderate to severe symptoms of uterine fibroids (UF) in adult women (over 18 years of age) of reproductive age.
Yselty is the only approved oral GnRH antagonist to offer flexible dosing options, with and without additional hormonal therapy, for women suffering from UF. The MHRA approval follows the granting of marketing authorization by the European Commission earlier in June 2022.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins